Drug
D1386 | Benoxinate
D
S
S01HA02 Oxybuprocaine
[S01HA] Local anesthetics
[S01H] LOCAL ANESTHETICS
[S01] OPHTHALMOLOGICALS
[S] Sensory organs
D04AB03 Oxybuprocaine
[D04AB] Anesthetics for topical use
[D04A] ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
[D04] ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
[D] Dermatological drugs
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| ELONGATION | mouse | neuron | Mitochondrial morphology and neurite area measurements | induce | 269 | |||
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| guinea pig | LD50 | intravenous | 4200ug/kg (4.2mg/kg) | Drugs in Japan Vol. -, Pg. 232, 1990. | |
| mouse | LD50 | intravenous | > 6800ug/kg (6.8mg/kg) | Drugs in Japan Vol. -, Pg. 232, 1990. | |
| guinea pig | LD50 | subcutaneous | 21mg/kg (21mg/kg) | Drugs in Japan Vol. -, Pg. 232, 1990. | |
| rabbit | LD50 | unreported | 5600ug/kg (5.6mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 24, Pg. 1957, 1974. | |
| rat | LD50 | intravenous | > 5600ug/kg (5.6mg/kg) | Drugs in Japan Vol. -, Pg. 232, 1990. | |
| rat | LD50 | subcutaneous | 60mg/kg (60mg/kg) | Drugs in Japan Vol. 6, Pg. 154, 1982. | |
| mouse | LD50 | subcutaneous | 42500ug/kg (42.5mg/kg) | Drugs in Japan Vol. 6, Pg. 154, 1982. | |
| rabbit | LD50 | subcutaneous | 30mg/kg (30mg/kg) | Drugs in Japan Vol. -, Pg. 232, 1990. | |
| 099A434 | 2-(4-amino-3-butoxy-benzoyl)oxyethyl-diethyl-ammonium chloride | 2-(4-amino-3-butoxybenzoyl)oxyethyl-diethylazanium chloride |
| 2-(Diethylamino)ethyl 4-amino-3-butoxy-benzoate | 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate | 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate (HCl) |
| 2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate | 2-Diethylaminoethyl 4-amino-3-butoxybenzoate | 3-Butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester |
| 3-Butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester | 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid | 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester |
| 4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester | 4-Amino-3-butoxybenzoic acid 2-diethylaminoethyl ester | 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester |
| 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [German] | 4675B | 99-43-4 |
| AB0218160 | AKOS005457803 | ALBB-025704 |
| API0015835 | AXQ0JYM303 | BBL003343 |
| BDBM50225499 | BENZOIC ACID, 4-AMINO-3-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER | BPBio1_000235 |
| BRD-K04185004-003-03-6 | BRN 2288926 | BS-18026 |
| BSPBio_000213 | Benoxil | Benoxinate |
| Benoxinate hydrochloride;Oxybuprocaine;Benoxinate;oxybuprocaine | Benoxinate;Conjucain | Benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7CI,8CI,9CI) |
| Butoxyaminobenzoyldiethylaminoethanol | CAS-5987-82-6 | CHEBI:309594 |
| CHEMBL1200 | Conjucain | D08319 |
| DB00892 | DTXSID7048530 | Dorsacain |
| Dorsacain | Epitope ID:122669 | FT-0659855 |
| GTPL7123 | HMS2235J23 | HMS3369H13 |
| HMS3604F05 | LS-35639 | MCULE-5566120451 |
| MFCD00242863 | MLS001332643 | MLS001332644 |
| Minims Oxybuprocaine | Monofree oxybuprocaine (TN) | NCGC00016667-01 |
| NCGC00016667-02 | NCGC00016667-05 | NS00002761 |
| Novescine | Novesin | Novesinol |
| Novesinol | Oxbarukain | Oxibuprocaina |
| Oxibuprocaina [INN-Spanish] | Oxibuprocainum | Oxibuprokain |
| Oxybucaine | Oxybucaine | Oxybuprocaine |
| Oxybuprocaine (INN) | Oxybuprocaine [INN:BAN] | Oxybuprocainum |
| Oxybuprocainum [INN-Latin] | Oxyriprocaine | Prescaina |
| Prestwick0_000057 | Prestwick1_000057 | Prestwick2_000057 |
| Prestwick3_000057 | Q1530958 | R1237 |
| S 749 | SBB065174 | SCHEMBL25087 |
| SMR000857098 | SPBio_002134 | ST45028778 |
| STK520615 | UNII-AXQ0JYM303 | ZINC2019492 |
| ZX-AN024218 | butoxyprocaine | diethylaminoethyl-4-amino-3-butoxybenzoate |